Company news
Jazz Pharmaceuticals plc news in 2025
Jazz Pharmaceuticals plc's news releases, calls and decks from 2025, newest first.
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
December 16, 2025
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
December 4, 2025
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
December 1, 2025
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
November 17, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
November 17, 2025
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarc...
November 16, 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
November 10, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies
November 10, 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
November 4, 2025
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
October 27, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
October 21, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
October 21, 2025
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
October 1, 2025
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
September 21, 2025
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
September 9, 2025
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
August 20, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
August 19, 2025
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
August 19, 2025
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
August 13, 2025
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
August 4, 2025
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
August 4, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
July 21, 2025
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
July 9, 2025
Nuevocor Strengthens Board with Appointment of Thierry Abribat
July 7, 2025
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
June 30, 2025
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
June 9, 2025
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
June 8, 2025
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
June 1, 2025
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
June 1, 2025
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
May 28, 2025
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 20, 2025
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
May 5, 2025
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference
April 29, 2025
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
April 24, 2025
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
April 22, 2025
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
April 21, 2025
Jazz Pharmaceuticals Completes Acquisition of Chimerix
April 20, 2025
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 25, 2025
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
March 18, 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
March 4, 2025
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
February 24, 2025
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
February 19, 2025
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
February 10, 2025
Calls in 2025
Decks in 2025
- Q3 2025 Earnings Presentation
Earnings · 24 slides · Nov 5, 2025
- Q4 2024 Earnings Presentation
Earnings · 27 slides · Feb 25, 2025
- 43rd Annual J.P. Morgan Healthcare Conference 2025
Conference · 27 slides · Jan 13, 2025